<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Previously, autologous Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-specific cytotoxic T-lymphocytes (CTL) were found to express the gamma and delta T-cell receptor and recognize <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> idiotype in a major histocompatibility complex (MHC) unrestricted fashion </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In this study, the authors established autologous CTL lines and clones specific for a B-cell follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: These CTL are <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specific and inhibited by antiimmunoglobulin monoclonal antibodies, but unlike the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-specific CTL, they are MHC restricted and express the alpha and <z:chebi fb="0" ids="36018">beta T</z:chebi>-cell receptor </plain></SENT>
<SENT sid="3" pm="."><plain>CONCLUSIONS: These studies suggest that different B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> can induce CTL of different phenotypes and MHC restriction </plain></SENT>
</text></document>